RESEARCH DIGEST / PRECURSOR
Nicotinamide Riboside in the Human Trial Literature
NR is the most clinically studied oral route to raising NAD+. The randomized trials, the dose-response, and the tolerability record — read as a rising stack of measured blood-NAD+ steps.
The short version
Nicotinamide riboside (NR) is a precursor — a building block the body converts into NAD+ (the fuel-handling helper molecule every cell uses). It belongs to the vitamin-B3 family, and of all the oral ways to raise NAD+, it is the one with the most randomized human trials behind it. In those trials, more NR meant more NAD+ in the blood, in a clean dose-response, and people generally tolerated it well. What stays unproven is whether that blood rise changes long-term health outcomes. This page lays out exactly what the nicotinamide riboside trials measured, with every number cited.
How nicotinamide riboside becomes NAD+
Nicotinamide riboside enters NAD+ synthesis by a route that skips the rate-limiting salvage enzyme. NRK kinases (NRK1/NRK2) convert NR to nicotinamide mononucleotide (NMN), which NMNAT enzymes then convert to NAD+ — a Preiss-Handler-independent path [5]. That kinetic shortcut is part of why NR is orally effective: it was shown to be uniquely and orally bioavailable in mice and humans, raising the whole-blood NAD+ metabolome including a more-than-25-fold rise in NAAD, an internal biomarker of NAD+ pathway flux [6].
Because NR sits two steps from NAD+ rather than being NAD+ itself, an NR trial measures a precursor, not direct NAD+ intake — a distinction that matters for reading every result below.
The dose-response: NR raises whole-blood NAD+
The defining NR finding is a clean dose-response in whole-blood NAD+. In a randomized, double-blind, placebo-controlled trial in healthy overweight adults, NR at 100, 300 and 1000 mg/day for 8 weeks raised whole-blood NAD+ by 22%, 51% and 142% respectively, with the elevation maintained throughout the study [4]. The orderly step from dose to NAD+ level is what makes NR's effect read as a true pharmacodynamic relationship rather than noise: each higher dose lands on its own measured tier. NR also did not cause flushing, did not elevate LDL cholesterol and did not disrupt one-carbon metabolism, and adverse events did not differ significantly from placebo at any dose [4].
The acute kinetics match the chronic picture. A single oral NR dose of 100-1000 mg raised whole-blood NAD+ dose-dependently, with 1000 mg producing roughly a 2.7-fold rise over 24 hours [6] — so the effect begins within a day, not only after weeks of loading. Chronic dosing then sustains it: 1000 mg/day for 6 weeks in a randomized crossover raised whole-blood NAD+ about 60% in healthy middle-aged and older adults [7]. Across acute single doses, 6-week and 8-week regimens, and different study populations, the direction and dose-dependence hold — a consistency that is itself a meaningful finding [4][6][7]. The specific doses used in research are laid out alongside the NMN figures on the dosage page.
What the NR metabolome reveals
One reason NR is the best-characterized oral NAD+ booster is that its effect leaves a clear biochemical fingerprint. Beyond raising NAD+ itself, oral NR raised nicotinic acid adenine dinucleotide (NAAD) more than 25-fold — NAAD is an internal biomarker of flux through the NAD+ biosynthetic pathway, so its rise confirms that the supplemented NR is genuinely feeding NAD+ synthesis rather than merely circulating [6]. That metabolomic readout, demonstrated in both mice and humans in the same study, is part of why NR's oral bioavailability is described as unique among the precursors [6].
The practical takeaway is that NR's blood-NAD+ rise is not an artifact of assay or absorption — the whole-blood NAD+ metabolome shifts in the direction synthesis predicts, across acute and chronic dosing [6][4]. Because the metabolite signature was reproduced in both species in a single controlled study, NR's oral route is one of the few NAD+-raising strategies validated by direct biochemical tracing rather than by blood NAD+ alone [6].
Tolerability and functional endpoints in NR trials
Across these randomized trials, NR was well tolerated. The 8-week dose-ranging trial reported no significant adverse-event difference from placebo at doses up to 1000 mg/day and no flushing — a meaningful contrast with high-dose nicotinic acid, which causes a prostaglandin-mediated flush [4]. The same trial found NR did not elevate LDL cholesterol and did not disrupt one-carbon metabolism, addressing two theoretical safety concerns about chronic methyl-donor consumption [4]. The 6-week crossover reported no serious adverse events at 1000 mg/day [7]. Higher doses have been tested for safety: NR up to 3000 mg/day was evaluated in the NR-SAFE context in Parkinson's disease.
Functional results are preliminary. The 6-week crossover showed a non-significant trend toward reduced aortic stiffness and lower systolic blood pressure, not a confirmed clinical effect [7]. Preclinically, NR has restored muscle and liver NAD+ and improved exercise capacity in a mouse mitochondrial-myopathy model [12], but that is an animal result. The consistent, reproducible NR result in humans remains the pharmacodynamic one — blood NAD+ rises dose-dependently — while harder clinical endpoints await larger trials, the same gap the 2025 Nature Metabolism review flagged across the field [16].
Is taking NAD orally effective?
Oral NAD+ itself is poorly absorbed intact, so swallowing "NAD+" capsules is not the studied route. The studied oral approach is to take precursors — NR or NMN — which randomized trials show reliably and dose-dependently raise whole-blood NAD+ (NR by 22%/51%/142% at 100/300/1000 mg/day) [4][6]. Effective for raising blood NAD+, yes; effective for hard clinical outcomes remains unproven.